Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Genomic and clinical features of SPOP mutations in prostate cancer

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, highlights the clinical and genomic features of SPOP mutations in prostate cancer. SPOP mutations occur in 6-15% of patients with prostate cancer. Previous studies have found that patients with SPOP mutations have superior responses to androgen deprivation therapy (ADT) and a more favorable response to abiraterone compared to patients with wild-type SPOP. A retrospective analysis of 59 patients with prostate cancer, who also had SPOP mutations, found that clinical outcomes to first-line ADT were longer than expected for a genomically-unselected cohort of patients. SPOP mutations appeared to be mutually exclusive with ERG fusions. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Dr Emmanuel Antonarakis, MBBCh, has received consultancy fees from AstraZeneca, Clovis and Janssen.